CHIRAL BISOXAZOLIDINES: A NEW CLASS OF LIGANDS FOR ASYMMETRIC CATALYSIS

许多生物活性化合物都是手性的，今天最畅销的药物中有50%以上是作为单一对映体上市的。对映体化合物的高需求和不断增长要求在不对称合成方面不断取得进展。特别是，新催化剂的开发仍然至关重要。具有刚性C2对称支架的手性双恶唑类化合物在不对称催化中具有广阔的应用前景。这类新的N，O-给体配体将被应用于挑战不对称碳-碳键的形成反应。通过这个奖项，有机合成：方法学和有机金属项目支持乔治敦大学化学系克里斯蒂安·沃尔夫教授的研究。沃尔夫教授的研究目标是开发用于不对称催化的新型手性双恶唑烷配体。将进行研究，以阐明双恶唑烷催化反应的机理，并努力微调这类配体的催化效率和不对称诱导。新型不对称催化剂的成功开发有望为合成复杂的手性靶分子提供新的工具。这将对制药、食品和农业行业产生影响。

Many biologically active compounds are chiral, and more than 50% of today's top-selling drugs are marketed as single enantiomers. The high and ever-increasing demand for enantiopure compounds requires constant progress in asymmetric synthesis. In particular, the development of new catalysts continues to be crucial. Chiral bisoxazolidines with a rigid C2-symmetric scaffold have very promising applications in asymmetric catalysis. This new class of N,O-donor ligands will be applied in challenging enantioselective carbon-carbon bond formation reactions. With this award, the Organic Synthesis: Methodology and Organometallic Program is supporting the research of Professor Christian Wolf of the Department of Chemistry at Georgetown University. Professor Wolf's research is aimed at the development of new chiral bisoxazolidine ligands for asymmetric catalysis. Studies to elucidate the mechanism of bisoxazolidine-catalyzed reactions and efforts to fine-tune the catalytic efficiency and asymmetric induction of this class of ligands will be undertaken. The successful development of new asymmetric catalysts is expected to provide new tools for the synthesis of complex chiral target molecules. This will have an impact on the pharmaceutical, food, and agricultural industries.